Thrombocytopenia: Optimizing approaches in cancer patients

Caroline Piatek, Mojtaba Akhtari

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of  hrombocytopenia in the cancer setting In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles In this issue of ONCOLOGY Dr Kuter insightfully summarizes the differential diagnosis and management of thrombocytopenia in cancer patients[1] Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of hrombocytopenia in the cancer setting[2] In patients receiving chemotherapy thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume29
Issue number4
Publication statusPublished - Jan 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this